Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Capital Leases for 6 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly Capital Leases changed 0.11% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.4 million through Dec 2025, changed 0.11% year-over-year, with the annual reading at $19.4 million for FY2025, 0.11% changed from the prior year.
  • Capital Leases hit $19.4 million in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $19.4 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $19.4 million in Q4 2024 to a low of $19.0 million in Q1 2021.
  • Historically, Capital Leases has averaged $19.3 million across 5 years, with a median of $19.3 million in 2023.
  • Biggest five-year swings in Capital Leases: grew 0.93% in 2021 and later fell 0.11% in 2025.
  • Year by year, Capital Leases stood at $19.1 million in 2021, then grew by 0.65% to $19.3 million in 2022, then increased by 0.44% to $19.4 million in 2023, then rose by 0.16% to $19.4 million in 2024, then fell by 0.11% to $19.4 million in 2025.
  • Business Quant data shows Capital Leases for RCKT at $19.4 million in Q4 2025, $19.4 million in Q3 2025, and $19.4 million in Q2 2025.